



Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026

August 17, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 17, 2026-- [Amylyx Pharmaceuticals, Inc.](https://investors.amylyx.com) (Nasdaq: AMLX) ("Amylyx" or the "Company") will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026. Amylyx's senior management team will host a conference call and audio webcast at 8:00 a.m. ET.

To access the conference call, please dial +1 (888) 880-3330 (U.S. & Canada) or +1 (646) 357-8766 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under "Events and Presentations" in the Investor section of the Company's website, <https://investors.amylyx.com/events-presentations>. The webcast will be archived and available for replay for 90 days following the event.

About Amylyx Pharmaceuticals

At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on four investigational therapies across several endocrine conditions and neurodegenerative diseases in which we believe can make the greatest impact. For more information, visit amylyx.com and follow us on [LinkedIn](#) and [X](#). For investors, please visit investors.amylyx.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20260817660841/en/>

Media

Amylyx Media Team
+1 (857) 320-6191
amylyxmediateam@amylyx.com

Investors

Lindsey Allen
Amylyx Pharmaceuticals, Inc.
+1 (857) 320-6244
Investors@amylyx.com

Source: Amylyx Pharmaceuticals, Inc.